Soleno Therapeutics, Inc. - Common Stock (SLNO)
Frequently Asked Questions About Soleno Therapeutics, Inc. - Common Stock (SLNO)
Are there any ongoing clinical trials by Soleno Therapeutics?
As a clinical-stage company, Soleno Therapeutics is involved in ongoing clinical trials for its lead product candidate, DCCR. Continued recruitment and ongoing assessments are central to advancing its current trials, which are critical for obtaining regulatory approval.
Does Soleno Therapeutics have partnerships?
Yes, Soleno Therapeutics has engaged in strategic partnerships and collaborations with various entities, including academic institutions and pharmaceutical companies, to foster innovation and leverage external expertise in its research and development endeavors.
How can investors get updated information about Soleno Therapeutics?
Investors can access updated information about Soleno Therapeutics through their official website, where they publish press releases, financial reports, and news on clinical trials. Additionally, the company's filings with the SEC provide detailed insights into their ongoing operations and strategic initiatives.
How does Soleno Therapeutics ensure regulatory compliance?
Soleno Therapeutics maintains regulatory compliance by adhering to guidelines established by the FDA and other global health authorities throughout its drug development and clinical trial protocols. This involves thorough documentation, rigorous quality control measures, and transparent communication during the approval process.
Is Soleno Therapeutics publicly traded?
Yes, Soleno Therapeutics is publicly traded under the ticker symbol 'SLNO' on the Nasdaq exchange. As a publicly listed company, they are required to adhere to regulatory standards that promote transparency and accountability to their investors.
What are Soleno Therapeutics' financial statuses?
Soleno Therapeutics is a publicly traded company, and its financial status is reported quarterly. Investors can find details on revenue, expenditures, clinical trial costs, and overall financial health through their quarterly earnings reports, which are publicly accessible.
What are the future prospects for Soleno Therapeutics?
The future prospects for Soleno Therapeutics hinge on the successful development and commercialization of its therapies, particularly DCCR for PWS. Positive trial outcomes and the potential for FDA approval could propel the company forward, positioning it strongly in the rare disease therapeutic market.
What are the risks associated with investing in Soleno Therapeutics?
Investing in Soleno Therapeutics carries several risks typical of biopharmaceutical companies, including high research and development costs, the potential for clinical trial setbacks, regulatory hurdles, and market acceptance risks. Investors should perform due diligence and understand these variables before making investment decisions.
What does Soleno Therapeutics, Inc. do?
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare diseases, particularly neurodevelopmental and metabolic disorders. Their lead product candidate, diazoxide choline controlled-release capsules (DCCR), aims to treat Prader-Willi Syndrome (PWS), a genetic disorder characterized by insatiable hunger and associated health issues.
What is diazoxide choline controlled-release capsule (DCCR)?
Diazoxide choline controlled-release capsules (DCCR) is Soleno Therapeutics' lead investigational drug designed to alleviate the hyperphagia (excessive hunger) and obesity associated with Prader-Willi Syndrome. DCCR operates by modulating hunger signals in the brain and has shown promise in clinical trials, leading to its potential approval for this indication.
What is Prader-Willi Syndrome?
Prader-Willi Syndrome (PWS) is a rare genetic disorder that affects multiple aspects of health and behavior, most notably leading to intense feelings of hunger and obesity due to metabolic dysfunction. Individuals with PWS often face developmental delays and cognitive impairments, making effective treatments crucial for improving their quality of life.
What is Soleno Therapeutics' strategy for growth?
Soleno Therapeutics aims for growth through the successful development and commercialization of their lead product candidates and expanding their pipeline to include additional therapies for rare diseases. The company also pursues strategic partnerships and collaborations to enhance its R&D capabilities and market reach.
What is the significance of the company’s stock performance?
The stock performance of Soleno Therapeutics is significant as it reflects investor confidence in the company's clinical and regulatory progress, as well as its overall business strategy. Significant developments, including trial results and product announcements, can lead to volatility in stock prices, which is closely monitored by investors.
What is the target market for Soleno Therapeutics?
Soleno Therapeutics primarily targets the market concerning rare genetic disorders, with a current focus on Prader-Willi Syndrome. This includes patients, caregivers, and healthcare providers who seek effective therapies and support for managing the challenges associated with such rare conditions.
What is the vision of Soleno Therapeutics, Inc.?
The vision of Soleno Therapeutics is to transform the lives of patients suffering from rare diseases, with a strong focus on harnessing cutting-edge science to create innovative therapies that address unmet medical needs. Their commitment is to bring effective treatments to market to improve the quality of life for patients and their families.
What makes Soleno Therapeutics unique?
Soleno Therapeutics stands out due to its dedicated focus on addressing rare diseases that currently have limited treatment options, particularly its emphasis on Prader-Willi Syndrome. The company's innovative approach to drug development, using proprietary formulations and advanced delivery methods, aims to create more effective therapies tailored to the specific needs of patients.
What stage of development is DCCR currently in?
As of the latest updates, DCCR has completed several phases of clinical trials, including pivotal Phase 3 trials. The company is working towards obtaining regulatory approval from the FDA, making it one of the few targeted therapies being evaluated for PWS.
Where is Soleno Therapeutics located?
Soleno Therapeutics is headquartered in San Diego, California. This strategic location allows the company to operate within one of the nation’s leading biotech hubs, providing access to a vast network of expertise and resources in the life sciences sector.
Who are the executives at Soleno Therapeutics?
Soleno Therapeutics is led by a team of experienced executives and industry veterans. As of the latest reports, the CEO is Anish Bhatnagar, M.D., who has extensive experience in the pharmaceutical industry, along with a seasoned management team that provides expertise in drug development, regulatory affairs, and commercialization.
What is the current price of Soleno Therapeutics, Inc. - Common Stock?
The current price of Soleno Therapeutics, Inc. - Common Stock is 72.16
When was Soleno Therapeutics, Inc. - Common Stock last traded?
The last trade of Soleno Therapeutics, Inc. - Common Stock was at 4:15 pm EDT on April 3rd, 2025
What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?
The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 589.46M
How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?
Soleno Therapeutics, Inc. - Common Stock has 8.17M shares outstanding.